Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-Part, Open Label Phase II Trial: Part One, Dose Escalation Safety; Part Two, Randomized/Comparing CDP791 Plus Carboplatin/Paclitaxel With Carboplatin/Paclitaxel Alone in Subjects With Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer

NCT00152477 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT00152477
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00152477 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-Part, Open Label Phase II Trial: Part One, Dose Escalation Safety; Part Two, Randomized/Comparing CDP791 Plus Carboplatin/Paclitaxel With Carboplatin/Paclitaxel Alone in Subjects With Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer
Lead sponsor
UCB Pharma
Phase
Phase 2
Overall status
Completed
Start date
August 15, 2005
Completion date
June 25, 2009
Enrollment
165 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-squamous non-small-cell lung cancer